An association representing independent service organizations has challenged the plans of GE Medical Systems of Milwaukee to acquire equipment service provider InnoServ Technologies of Arlington, TX. The Independent Service Network International of
An association representing independent service organizations has challenged the plans of GE Medical Systems of Milwaukee to acquire equipment service provider InnoServ Technologies of Arlington, TX. The Independent Service Network International of Atlanta filed a public comment on Sept. 15 in a Washington, DC, federal court, taking issue with the deal just as GE claimed to have finalized the acquisition.
GE announced in April its plan to acquire InnoServ, which provides third-party service for a large number of GE scanners. The U.S. Department of Justice initially opposed the purchase, believing that the acquisition could reduce competition in the multivendor service market. The Justice Department dropped its opposition, however, after reaching a settlement with GE in which the company agreed to sell off InnoServs Prevu diagnostic software (SCAN 7/22/98).
GE on Sept. 16 reported that the boards of both companies had approved the deal and that the acquisition was complete. ISNI believes the companies may be moving too quickly, however. The acquisition still must be approved by the U.S. District Court for the District of Columbia, as is the case in all situations in which the federal government offers to settle an antitrust case, according to Ronald Katz, an attorney with Coudert Brothers in San Francisco. ISNI filed its challenge as part of the public comment requirements regarding the case.
ISNIs comment claims that selling Prevu is no solution for the loss of competition that will occur if the acquisition goes through, and asserts that the Justice Department has not provided enough information on the impact the deal will have on competition for multivendor service. The complaint asks the court to appoint a special master to more fully investigate the impact the deal would have on the market. Katz believes that the court could rule on the comments and pass judgment on the acquisition in the next several months.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.